Cargando…

Combined inhibition of BET proteins and class I HDACs synergistically induces apoptosis in urothelial carcinoma cell lines

BACKGROUND: New efficient therapies for urothelial carcinoma (UC) are urgently required. Small-molecule drugs targeting chromatin regulators are reasonable candidates because these regulators are frequently mutated or deregulated in UC. Indeed, in previous work, Romidepsin, which targets class I his...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hölscher, Alexander S., Schulz, Wolfgang A., Pinkerneil, Maria, Niegisch, Günter, Hoffmann, Michèle J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5755363/ https://www.ncbi.nlm.nih.gov/pubmed/29312470 http://dx.doi.org/10.1186/s13148-017-0434-3

Ejemplares similares

Evaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma Cell Lines
por: Pinkerneil, Maria, et al.
Publicado: (2016)

Effects of novel HDAC inhibitors on urothelial carcinoma cells
por: Kaletsch, Aline, et al.
Publicado: (2018)

The New Immortalized Uroepithelial Cell Line HBLAK Contains Defined Genetic Aberrations Typical of Early Stage Urothelial Tumors
por: Hoffmann, Michèle J., et al.
Publicado: (2016)

Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine
por: Isono, Makoto, et al.
Publicado: (2017)

Downregulation of Cell Cycle and Checkpoint Genes by Class I HDAC Inhibitors Limits Synergism with G2/M Checkpoint Inhibitor MK-1775 in Bladder Cancer Cells
por: Hoffmann, Michèle J., et al.
Publicado: (2021)

HDAC5 Expression in Urothelial Carcinoma Cell Lines Inhibits Long-Term Proliferation but Can Promote Epithelial-to-Mesenchymal Transition
por: Jaguva Vasudevan, Ananda Ayyappan, et al.
Publicado: (2019)

Combination of Decitabine and Entinostat Synergistically Inhibits Urothelial Bladder Cancer Cells via Activation of FoxO1
por: Wang, Chenyin, et al.
Publicado: (2020)

HERV-K and LINE-1 DNA Methylation and Reexpression in Urothelial Carcinoma
por: Kreimer, Ulrike, et al.
Publicado: (2013)

Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling
por: Heinemann, Anja, et al.
Publicado: (2015)

Canonical Notch signalling is inactive in urothelial carcinoma
por: Greife, Annemarie, et al.
Publicado: (2014)

Multifaceted Mechanisms of Cisplatin Resistance in Long-Term Treated Urothelial Carcinoma Cell Lines
por: Skowron, Margaretha A., et al.
Publicado: (2018)

Histone deacetylase 8 is deregulated in urothelial cancer but not a target for efficient treatment
por: Lehmann, Maria, et al.
Publicado: (2014)

Diagnostic and prognostic value of long noncoding RNAs as biomarkers in urothelial carcinoma
por: Droop, Johanna, et al.
Publicado: (2017)

Knockdown of UTX/KDM6A Enriches Precursor Cell Populations in Urothelial Cell Cultures and Cell Lines
por: Lang, Alexander, et al.
Publicado: (2020)

Differential Effects of Histone Acetyltransferase GCN5 or PCAF Knockdown on Urothelial Carcinoma Cells
por: Koutsogiannouli, Evangelia A., et al.
Publicado: (2017)

Epigenetic Treatment of Urothelial Carcinoma Cells Sensitizes to Cisplatin Chemotherapy and PARP Inhibitor Treatment
por: Thy, Sophia, et al.
Publicado: (2021)

Various Mechanisms Involve the Nuclear Factor (Erythroid-Derived 2)-Like (NRF2) to Achieve Cytoprotection in Long-Term Cisplatin-Treated Urothelial Carcinoma Cell Lines
por: Skowron, Margaretha A., et al.
Publicado: (2017)

Distinctive mutational spectrum and karyotype disruption in long-term cisplatin-treated urothelial carcinoma cell lines
por: Skowron, Margaretha A., et al.
Publicado: (2019)

Distinct mechanisms contribute to acquired cisplatin resistance of urothelial carcinoma cells
por: Höhn, Annika, et al.
Publicado: (2016)

Phenotype plasticity rather than repopulation from CD90/CK14+ cancer stem cells leads to cisplatin resistance of urothelial carcinoma cell lines
por: Skowron, Margaretha A., et al.
Publicado: (2015)

The long noncoding RNA HOTAIR has tissue and cell type-dependent effects on HOX gene expression and phenotype of urothelial cancer cells
por: Heubach, Judith, et al.
Publicado: (2015)

Proteomic and transcriptomic profiles of human urothelial cancer cells with histone deacetylase 5 overexpression
por: Jaguva Vasudevan, Ananda Ayyappan, et al.
Publicado: (2022)

Combination BET Family Protein and HDAC Inhibition Synergistically Elicits Chondrosarcoma Cell Apoptosis Through RAD51-Related DNA Damage Repair
por: Huan, Songwei, et al.
Publicado: (2020)

Establishment and Evaluation of Dual HDAC/BET Inhibitors as Therapeutic Options for Germ Cell Tumors and Other Urological Malignancies
por: Burmeister, Aaron, et al.
Publicado: (2022)

Multiple Mechanisms Mediate Resistance to Sorafenib in Urothelial Cancer
por: Knievel, Judith, et al.
Publicado: (2014)

Concomitant downregulation of the imprinted genes DLK1 and MEG3 at 14q32.2 by epigenetic mechanisms in urothelial carcinoma
por: Greife, Annemarie, et al.
Publicado: (2014)

Predicting immune checkpoint inhibitor response in urothelial carcinoma: another step in personalised medicine?
por: Niegisch, Günter
Publicado: (2019)

Many Different LINE-1 Retroelements Are Activated in Bladder Cancer
por: Whongsiri, Patcharawalai, et al.
Publicado: (2020)

BET inhibition in advanced cutaneous T cell lymphoma is synergistically potentiated by BCL2 inhibition or HDAC inhibition
por: Kim, Sa Rang, et al.
Publicado: (2018)

Inhibitors of class I HDACs and of FLT3 combine synergistically against leukemia cells with mutant FLT3
por: Wachholz, Vanessa, et al.
Publicado: (2021)

Induction of USP17 by combining BET and HDAC inhibitors in breast cancer cells
por: Borbely, Gabor, et al.
Publicado: (2015)

Hydroxygenkwanin Inhibits Class I HDAC Expression and Synergistically Enhances the Antitumor Activity of Sorafenib in Liver Cancer Cells
por: Chen, Chi-Yuan, et al.
Publicado: (2020)

Basic Hallmarks of Urothelial Cancer Unleashed in Primary Uroepithelium by Interference with the Epigenetic Master Regulator ODC1
por: Erichsen, Lars, et al.
Publicado: (2020)

Alterations of Chromatin Regulators in the Pathogenesis of Urinary Bladder Urothelial Carcinoma
por: Hoffmann, Michèle J., et al.
Publicado: (2021)

Regulating the Regulators: The Post-Translational Code of Class I HDAC1 and HDAC2
por: Segré, Chiara V., et al.
Publicado: (2011)

Targeting Epigenetic Regulators with HDAC and BET Inhibitors to Modulate Muscle Wasting
por: Nevi, Lorenzo, et al.
Publicado: (2023)

Truncated Isoforms of lncRNA ANRIL Are Overexpressed in Bladder Cancer, But Do Not Contribute to Repression of INK4 Tumor Suppressors
por: Hoffmann, Michèle J., et al.
Publicado: (2015)

Inhibition of BET Proteins and Histone Deacetylase (HDACs): Crossing Roads in Cancer Therapy
por: Manzotti, Gloria, et al.
Publicado: (2019)

Physiological Roles of Class I HDAC Complex and Histone Demethylase
por: Hayakawa, Tomohiro, et al.
Publicado: (2011)

Ring size changes in the development of class I HDAC inhibitors
por: Cho, Er-Chieh, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rmp32dg0alc20h195in4ftt6tr